A Phase II Trial of ZD1839 (IRESSA) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction.

Trial Profile

A Phase II Trial of ZD1839 (IRESSA) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 Planned end date changed from 1 Jan 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2011 Planned end date changed from 1 Dec 2009 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top